HRP20180319T1 - Predlijek adrenomedulina baziran na polietilen glikolu i njegova uporaba - Google Patents

Predlijek adrenomedulina baziran na polietilen glikolu i njegova uporaba Download PDF

Info

Publication number
HRP20180319T1
HRP20180319T1 HRP20180319TT HRP20180319T HRP20180319T1 HR P20180319 T1 HRP20180319 T1 HR P20180319T1 HR P20180319T T HRP20180319T T HR P20180319TT HR P20180319 T HRP20180319 T HR P20180319T HR P20180319 T1 HRP20180319 T1 HR P20180319T1
Authority
HR
Croatia
Prior art keywords
acute
ali
group
pulmonary
ards
Prior art date
Application number
HRP20180319TT
Other languages
English (en)
Inventor
Ingo Flamme
Johannes KÖBBERLING
Hans-Georg Lerchen
Nils Griebenow
Rudolf Schohe-Loop
Sven WITTROCK
Maria KÖLLNBERGER
Frank Wunder
Gorden Redlich
Andreas Knorr
July MARLEY
Iain PRITCHARD
Original Assignee
Bayer Intellectual Property Gmbh
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property Gmbh, Bayer Pharma Aktiengesellschaft filed Critical Bayer Intellectual Property Gmbh
Publication of HRP20180319T1 publication Critical patent/HRP20180319T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)

Claims (10)

1. Lijek, koji sadrži spoj formule (I) [image] u kojoj n predstavlja broj 0, 1, 2 ili 3, R1 predstavlja vodik, metil, etil, n-propil ili izopropil, R2 predstavlja ravni ili razgranatni PEG 20kDa do 80kDa zaklopljen s metoksi skupinom, ili jedna od njegovih soli, njegovi solvati ili solvati njegovih soli, u kombinaciji s inertnim netoksičnim farmaceutski prikladnim ekscipijentom, pri čemu je lijek u farmaceutskom obliku za inhalaciju.
2. Lijek prema zahtjevu 1, naznačen time da je spoj s formulom (I) definiran kako slijedi: n predstavlja broj 1 ili 2, R1 predstavlja vodik ili metil, R2 predstavlja ravni PEG 40kDa zaklopljen s metoksi skupinom.
3. Lijek prema bilo kojem od zahtjeva 1 do 2, naznačen time da je spoj s formulom (I) definiran kako slijedi: n predstavlja broj 1 ili 2, R1 predstavlja vodik, R2 predstavlja ravni PEG 40kDa zaklopljen s metoksi skupinom.
4. Lijek prema bilo kojem od zahtjeva 1 do 3, naznačen time da je farmaceutski oblik za inhalaciju odabran iz skupine koja se sastoji od inhalatora praha i nebulizatora.
5. Lijek prema bilo kojem od zahtjeva 1 do 4, naznačen time da je nadalje u kombinaciji s dodatnim aktivnim sastojkom odabranim iz skupine koja se sastoji od ACE inhibitora, antagonista angiotenzinskih receptora, agonista beta-2 receptora, inhibitora fosfodiesteraze, agonista glukokortikoidnog receptora, diuretika, rekombinantnog angiotenzin pretvarajućeg enzima-2 i acetilsalicilne kiseline.
6. Lijek prema zahtjevu 5, naznačen time da je dodatni aktivni sastojak odabran iz skupine koju čine ACE inhibitor odabran iz skupine koju čine enalapril, kinapril, kaptopril, lizinopril, ramipril, delapril, fosinopril, perindopril, cilazapril, imidapril, benazepril, moeksipril, spirapril i trandopril, antagonist receptora angiotenzina, odabran iz skupine koju čine losartan, kandesartan, valsartan, telmisartan i embusartan, agonist beta-2 receptora, odabran iz skupine koju čine salbutamol, pirbuterol, salmeterol, terbutalin, fenoterol, tulobuterol, klenbuterol, reproterol i formoterol, inhibitor fosfodiesteraze (PDE) odabran iz skupine koju čine milrinon, amrinon, pimobendan, cilostazol, sildenafil, vardenafil i tadalafil, agonist glukokortikoidnog receptora odabran iz skupine koju čine kortizol, kortizon, hidrokortizon, prednizon, metil-metilprednizolon, predniliden, deflazakor, fluokortolon, triamcinolon, deksametazon i betametazon, diuretik, furosemid, torasemid i hidroklorotiazid, rekombinantni angiotenzin pretvarajući enzim-2 i acetilsalicilna kiselina.
7. Lijek prema bilo kojem od zahtjeva 1 do 6 naznačen time da je za uporabu za liječenje i/ili sprječavanje kardiovaskularnog, edematoznog i/ili upalnog poremećaja odabranog iz skupine koju čine zatajenje srca, koronarna bolest srca, ishemijski i/ili hemoragijski moždani udar, hipertenzija, plućna hipertenzija, periferna arterijska okluzivna bolest, preeklampsija, kronična opstruktivna plućna bolest, astma, akutni i/ili kronični plućni edem, alergijski alveolitis i/ili pneumonitis zbog udisanja organske prašine i čestica gljivičnog, aktinomicetičkog ili drugog podrijetla, i/ili akutni kemijski bronhitis, akutni i/ili kronični kemijski plućni edem, neurogeni plućni edem, akutne i/ili kronične plućne manifestacije zbog zračenja, akutni i/ili kronični intersticijski plućni poremećaji, akutna plućna ozljeda/sindrom akutnog respiracijskog distresa (ALI/ARDS) u odrasloj dobi ili kod djeteta uključujući novorođenče, ALI/ARDS sekundarna uz upalu pluća i sepsu, aspiracijska upala pluća i ALI/ARDS sekundarna uz aspiraciju, ALI/ARDS sekundarna uz udisanje dimnih plinova, akutna ozljeda pluća izazvana transfuzijom (TRALI), ALI/ARDS i/ili akutna plućna insuficijencija nakon operacije, traume i/ili opeklina, i/ili oštećenje pluća izazvano mehaničkom ventilacijom (VILI), ozljeda pluća nakon aspiracije mekonija, plućna fibroza, planinska bolest, glomerulonefritis, akutna ozljeda bubrega, kardiorenalni sindrom, limfedem, upalna bolest crijeva, sepsa, septički šok, sindrom sustavnog upalnog odgovora (SIRS) neinfektivnog podrijetla, upalna bolest crijeva i urtikarija, koji sadrži davanje čovjeku ili životinji aktivne količine lijeka prema bilo kojem od zahtjeva 1 do 6.
8. Lijek prema zahtjevu 7, naznačen time da je kardiovaskularni, edematozni i/ili upalni poremećaj odabran iz skupine koju čine plućna hipertenzija, kronična opstruktivna plućna bolest, astma, akutni i/ili kronični plućni edem, alergijski alveolitis i/ili pneumonitis zbog udisanja organske prašine i čestica gljivičnog, aktinomicetičkog ili drugog podrijetla, i/ili akutni kemijski bronhitis, akutni i/ili kronični kemijski plućni edem, neurogeni plućni edem, akutne i/ili kronične plućne manifestacije zbog zračenja, akutni i/ili kronični intersticijski plućni poremećaji, akutna plućna ozljeda/sindrom akutnog respiracijskog distresa (ALI/ARDS) u odrasloj dobi ili kod djeteta uključujući novorođenče, ALI/ARDS sekundarna uz upalu pluća i sepsu, aspiracijska upala pluća i ALI/ARDS sekundarna uz aspiraciju, ALI/ARDS ALI/ARDS sekundarna uz udisanje dimnih plinova, akutna ozljeda pluća izazvana transfuzijom (TRALI), ALI/ARDS i/ili akutna plućna insuficijencija nakon operacije, traume i/ili opeklina, i/ili oštećenje pluća izazvano mehaničkom ventilacijom (VILI), ozljeda pluća nakon aspiracije mekonija, plućna fibroza, planinska bolest, koji sadrži davanje čovjeku ili životinji aktivne količine lijeka prema bilo kojem od zahtjeva 1 do 6.
9. Spoj s formulom (Ia) [image] ili jedna od njegovih soli, njegovi solvati ili solvati njegovih soli.
10. Spoj s formulom (II) [image]
HRP20180319TT 2011-11-03 2018-02-21 Predlijek adrenomedulina baziran na polietilen glikolu i njegova uporaba HRP20180319T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11187735 2011-11-03
EP15192265.5A EP3075395B1 (en) 2011-11-03 2012-10-30 Polyethylene glycol based prodrug of adrenomedullin and use thereof

Publications (1)

Publication Number Publication Date
HRP20180319T1 true HRP20180319T1 (hr) 2018-03-23

Family

ID=47146369

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20160285TT HRP20160285T1 (hr) 2011-11-03 2016-03-21 Predlijek adrenomedulina na bazi polietilen glikola i njegova uporaba
HRP20180319TT HRP20180319T1 (hr) 2011-11-03 2018-02-21 Predlijek adrenomedulina baziran na polietilen glikolu i njegova uporaba

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20160285TT HRP20160285T1 (hr) 2011-11-03 2016-03-21 Predlijek adrenomedulina na bazi polietilen glikola i njegova uporaba

Country Status (45)

Country Link
US (3) US9603936B2 (hr)
EP (2) EP2773376B1 (hr)
JP (2) JP5995984B2 (hr)
KR (2) KR101965467B1 (hr)
CN (2) CN107412740B (hr)
AR (2) AR088582A1 (hr)
AU (2) AU2012331244B2 (hr)
BR (1) BR112014010708B1 (hr)
CA (1) CA2854134C (hr)
CL (1) CL2014000948A1 (hr)
CO (1) CO7020863A2 (hr)
CR (1) CR20140184A (hr)
CU (1) CU24184B1 (hr)
CY (2) CY1117354T1 (hr)
DK (2) DK3075395T3 (hr)
DO (2) DOP2014000078A (hr)
EA (2) EA029410B1 (hr)
EC (2) ECSP14013326A (hr)
ES (2) ES2659195T3 (hr)
GT (1) GT201400085A (hr)
HK (1) HK1246147A1 (hr)
HR (2) HRP20160285T1 (hr)
HU (2) HUE036535T2 (hr)
IL (3) IL232037B (hr)
IN (1) IN2014CN03290A (hr)
JO (2) JOP20190001B1 (hr)
LT (1) LT3075395T (hr)
MA (1) MA35618B1 (hr)
ME (1) ME02379B (hr)
MX (2) MX361287B (hr)
MY (2) MY173372A (hr)
NO (1) NO3075395T3 (hr)
PE (2) PE20141219A1 (hr)
PL (2) PL2773376T3 (hr)
PT (1) PT3075395T (hr)
RS (2) RS56819B1 (hr)
SG (2) SG11201400924TA (hr)
SI (2) SI3075395T1 (hr)
TN (1) TN2014000185A1 (hr)
TR (1) TR201802124T4 (hr)
TW (2) TWI653051B (hr)
UA (1) UA111098C2 (hr)
UY (2) UY37922A (hr)
WO (1) WO2013064508A1 (hr)
ZA (1) ZA201600434B (hr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN03213A (hr) * 2011-11-03 2015-05-22 Bayer Ip Gmbh
EP2896400A1 (en) * 2014-01-17 2015-07-22 Université Catholique De Louvain Method for increasing the bioavailability of inhaled compounds
US11414474B2 (en) 2014-03-20 2022-08-16 University Of Miyazaki Long-acting adrenomedullin derivatives
AU2015323769A1 (en) 2014-09-26 2017-04-13 Bayer Pharma Aktiengesellschaft Stabilized adrenomedullin derivatives and use thereof
SG10202008963QA (en) 2015-09-18 2020-10-29 Univ Miyazaki Long-acting adrenomedullin derivative
CN110678550B (zh) 2017-03-29 2023-11-14 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
CA3143584A1 (en) 2019-06-18 2020-12-24 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
JPWO2021112220A1 (hr) * 2019-12-05 2021-06-10
US20230364245A1 (en) 2020-04-03 2023-11-16 Bayer Aktiengesellschaft Pharmaceutical formulations polyethylene glycol-based prodrugs of adrenomedullin and use
MX2022012332A (es) * 2020-04-03 2022-10-27 Bayer Ag Formulaciones farmaceuticas liquidas de profarmacos a base de polietilenglicol de adrenomedulina y su uso.
CN116438200A (zh) 2020-09-10 2023-07-14 普雷西里克斯公司 针对fap的抗体片段
CN112457218B (zh) * 2020-11-05 2022-08-09 宁夏医科大学 2,4-二氨基丁酸衍生物的合成方法
IL310248A (en) 2021-08-20 2024-03-01 Bayer Ag A process for the preparation of polyethylene glycol-modified adrenomedullin, its intermediates and their use
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5020040A (en) * 1987-06-24 1991-05-28 Digital Equipment Corporation Overwriting system for magneto-optical recording with self timing track
US4812590A (en) 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
CA2292902C (en) 1999-12-24 2012-12-18 Alain Cadieux Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2004019993A1 (en) 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
US7705045B2 (en) 2002-11-14 2010-04-27 Syntarga, B.V. Prodrugs built as multiple self-elimination-release spacers
PT1646813E (pt) 2003-07-23 2013-07-09 Ppg Ind Ohio Inc Vedante compósito e conjunto de janela
EP2087910B1 (en) 2004-03-23 2022-05-04 Ascendis Pharma GmbH Polymeric prodrugs
CA2567478C (en) 2004-05-24 2014-04-01 Institut De Cardiologie De Montreal Labelled adrenomedullin derivatives and their use for imaging and therapy
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
WO2008075968A1 (en) * 2006-12-20 2008-06-26 Ge Healthcare As Contrast agents
EP2155781B1 (en) * 2007-05-11 2013-03-13 Institut de Cardiologie de Montréal Labelled adrenomedullin derivatives and their use for imaging and therapy.
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
IN2014DN03213A (hr) * 2011-11-03 2015-05-22 Bayer Ip Gmbh

Also Published As

Publication number Publication date
IL232037B (en) 2018-12-31
IL258229B (en) 2020-02-27
HK1246147A1 (zh) 2018-09-07
CN107412740B (zh) 2021-02-09
NO3075395T3 (hr) 2018-04-21
TR201802124T4 (tr) 2018-03-21
DOP2018000203A (es) 2018-10-15
IL252281A0 (en) 2017-08-31
AU2017203423A1 (en) 2017-06-08
IL232037A0 (en) 2014-05-28
JOP20190001A1 (ar) 2017-06-16
HRP20160285T1 (hr) 2016-04-22
IL252281B (en) 2021-01-31
KR20180108892A (ko) 2018-10-04
IL258229A (en) 2018-06-28
TWI653051B (zh) 2019-03-11
CL2014000948A1 (es) 2014-09-05
BR112014010708A2 (pt) 2017-04-25
PE20181493A1 (es) 2018-09-18
IN2014CN03290A (hr) 2015-07-03
US20160367636A1 (en) 2016-12-22
WO2013064508A1 (en) 2013-05-10
JP5995984B2 (ja) 2016-09-21
GT201400085A (es) 2015-03-05
TWI583396B (zh) 2017-05-21
EP2773376A1 (en) 2014-09-10
ES2568063T3 (es) 2016-04-27
MY194197A (en) 2022-11-21
EP3075395A1 (en) 2016-10-05
CN103998063B (zh) 2016-09-21
JP2014532682A (ja) 2014-12-08
JP6177975B2 (ja) 2017-08-09
KR102004668B1 (ko) 2019-07-26
CN107412740A (zh) 2017-12-01
CY1117354T1 (el) 2017-04-26
EA201600495A1 (ru) 2016-10-31
HUE027333T2 (en) 2016-09-28
AR088582A1 (es) 2014-06-18
NZ622997A (en) 2015-12-24
MX350341B (es) 2017-09-04
US9649363B2 (en) 2017-05-16
CY1119897T1 (el) 2018-06-27
CU20140051A7 (es) 2014-10-02
EP3075395B1 (en) 2017-11-22
RS56819B1 (sr) 2018-04-30
AU2012331244A1 (en) 2014-04-17
EA025631B1 (ru) 2017-01-30
DOP2014000078A (es) 2014-07-15
NZ714621A (en) 2017-10-27
MX361287B (es) 2018-12-03
TN2014000185A1 (en) 2015-09-30
ZA201600434B (en) 2017-05-31
MA35618B1 (fr) 2014-11-01
MY173372A (en) 2020-01-21
SI3075395T1 (en) 2018-03-30
DK2773376T3 (en) 2016-04-18
ES2659195T3 (es) 2018-03-14
TW201332573A (zh) 2013-08-16
UY34419A (es) 2013-05-31
BR112014010708B1 (pt) 2021-03-02
CA2854134A1 (en) 2013-05-10
SG11201400924TA (en) 2014-09-26
UA111098C2 (uk) 2016-03-25
PL3075395T3 (pl) 2018-04-30
KR20150000462A (ko) 2015-01-02
ME02379B (me) 2016-06-20
PT3075395T (pt) 2018-02-13
MX2014004384A (es) 2014-04-30
EA029410B1 (ru) 2018-03-30
PE20141219A1 (es) 2014-09-13
JO3385B1 (ar) 2019-03-13
SI2773376T1 (sl) 2016-05-31
SG10201607516SA (en) 2016-10-28
HUE036535T2 (hu) 2018-07-30
LT3075395T (lt) 2018-02-26
US10035818B2 (en) 2018-07-31
ECSP18071104A (es) 2018-10-31
KR101965467B1 (ko) 2019-04-03
EA201400528A1 (ru) 2014-10-30
PL2773376T3 (pl) 2016-07-29
CN103998063A (zh) 2014-08-20
CO7020863A2 (es) 2014-08-11
CU24184B1 (es) 2016-07-29
AR113830A2 (es) 2020-06-17
AU2017203423B2 (en) 2019-01-31
EP2773376B1 (en) 2016-01-13
CR20140184A (es) 2014-05-27
UY37922A (es) 2018-11-30
RS54623B1 (en) 2016-08-31
JOP20190001B1 (ar) 2022-03-14
JP2017014264A (ja) 2017-01-19
US9603936B2 (en) 2017-03-28
AU2012331244B2 (en) 2017-06-15
DK3075395T3 (en) 2018-02-19
CA2854134C (en) 2020-04-21
US20170204137A1 (en) 2017-07-20
TW201720467A (zh) 2017-06-16
ECSP14013326A (es) 2014-05-31
US20140287984A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
HRP20180319T1 (hr) Predlijek adrenomedulina baziran na polietilen glikolu i njegova uporaba
JP7169693B2 (ja) 呼吸器疾患の治療
RU2008129600A (ru) Комбинация и фармацевтический препарат для лечения воспалительных заболеваний
Frampton QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease
HRP20130835T1 (hr) Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru
RU2019100425A (ru) Новая доза и препаративная форма
JP2013531056A5 (hr)
RU2006132040A (ru) Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
CA2550841A1 (en) Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
JP2012517987A5 (ja) 吸入用の医薬組成物のｆｐｄ特性を設定する方法
ES2430596T3 (es) 5-(2-{[6-(2,2-Difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1H)-ona para el tratamiento de la función pulmonar
JP2016510804A5 (hr)
NZ627837A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
WO2011136754A1 (en) A medicament developed for the treatment of respiratory diseases
KR20220158030A (ko) 급성 폐손상 치료용 5-아미노-2,3-디히드로-1,4-프탈라진디온
CN116075306A (zh) 用于治疗冠状病毒感染的化合物
ES2610104T3 (es) Aclidinio para el uso en la mejora de la calidad del sueño en pacientes con enfermedades respiratorias
KR20110123740A (ko) 5-(2-｛［6-(2,2-디플루오로-2-페닐에톡시)헥실］아미노｝-1-히드록시에틸)-8-히드록시퀴놀린-2(1ｈ)-온 및 이의 폐질환 치료에서의 용도
EP2563364A1 (en) Combination of carmoterol and fluticasone for use in the treatment respiratory diseases
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
CN104274426A (zh) 昂丹司琼细粉、昂丹司琼气溶胶组合物及其用途
ES2279004T3 (es) Combinacion de un inhibidor de pde y un antagonista de los receptores de leucotrienos.
EP2611431A2 (en) Formulation comprising cellobiose
US20230263768A1 (en) Water-soluble artesunate-based therapy for coronavirus infection
JP2023525759A (ja) ウイルス性呼吸器疾患を治療するために吸入されるスタチン